CARDIFF ONCOLOGY INC

Cardiff Oncology stock dips 1.06% as biotech sector cools—track the $0.93 Nasdaq share, 29% YTD slide, and peer‑benchmarks for investors.

Cardiff Oncology shares tumble 29% as investors await breakthrough clinical data, while sector volatility pressures biotech stocks and highlights the need for a strong partnership or regulatory win to revive investor confidence.

Cardiff Oncology shares hit a 24‑hour rise of 4.49 % to USD 0.96, amid solid market cap and biotech focus on solid‑tumor therapies.